Advertisement Salong Debbarma, Author at Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by Salong Debbarma

Novartis India acquires Pfizer brands for $132m

The purchase adds an established hypertension brand to Novartis’ cardiovascular range. Novartis India’s board cleared the deal, after which the company signed an asset purchase agreement and trademark